[1]刘敏芝,李运泽.幽门螺杆菌的治疗现状[J].医学信息,2021,34(15):35-38.[doi:10.3969/j.issn.1006-1959.2021.15.010]
　LIU Min-zhi,LI Yun-ze.Current Status of Treatment of Helicobacter Pylori[J].Medical Information,2021,34(15):35-38.[doi:10.3969/j.issn.1006-1959.2021.15.010]
点击复制

幽门螺杆菌的治疗现状()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年15期
页码:
35-38
栏目:
综述
出版日期:
2021-08-01

文章信息/Info

Title:
Current Status of Treatment of Helicobacter Pylori
文章编号:
1006-1959（2021）15-0035-04
作者:
刘敏芝; 李运泽
（柳州市人民医院消化内科，广西 柳州 545006）
Author(s):
LIU Min-zhi; LI Yun-ze
(Department of Gastroenterology,Liuzhou People’s Hospital,Liuzhou 545006,Guangxi,China)
关键词:
幽门螺杆菌; Ⅰ类致癌物; 铋剂; Hp尿素酶
Keywords:
Helicobacter pylori; Class I carcinogen; Bismuth agent; Hp urease
分类号:
R378.2
DOI:
10.3969/j.issn.1006-1959.2021.15.010
文献标志码:
A
摘要:
幽门螺杆菌（Hp）与胃癌及癌前病变的发生密切相关，国际癌症研究机构和世界卫生组织已经将 Hp 划分为Ⅰ类致癌物，Hp根除治疗利大于弊，目前根除Hp感染已成为全球关注的热点。Hp感染率逐渐升高，再感染机率也逐年上升，随着抗生素耐药发生率的不断升高，首次根除Hp治疗的成功率仍较低。国内外有大量研究探索更有效的根除Hp的新方案，如高剂量二联疗法、Hp的靶向治疗、Hp疫苗的研发等。本文主要就近年来根除Hp的相关研究进行综述，以期为临床治疗Hp感染提供参考。
Abstract:
Helicobacter pylori (Hp) is closely related to the occurrence of gastric cancer and precancerous lesions. The International Agency for Research on Cancer and the World Health Organization have classified Hp as a Class I carcinogen. The benefits of Hp eradication treatment outweigh the disadvantages. At present, eradication of Hp infection has become a global concern. Hot spot.The Hp infection rate is gradually increasing, and the re-infection rate is also increasing year by year. With the increasing incidence of antibiotic resistance, the success rate of the first eradication of Hp treatment is still low.There are a large number of studies at home and abroad to explore more effective new solutions to eradicate Hp, such as high-dose dual therapy, Hp targeted therapy, and the development of Hp vaccines.This article mainly reviews the related research on Hp eradication in recent years, hoping to provide reference for clinical treatment of Hp infection.

参考文献/References:

[1]Nagy P,Johansson S,Molloy-Bland M.Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USA[J].Gut Pathogens,2016,8(1):8. [2]Wroblewski LE,Peek RM Jr.Helicobacter pylori in gastric carcinogenesis:Mechanisms[J].Gastroenterol Clin North Am,2013,42(2):285-298． [3]Malfertheiner P,Megraud F,O’Morain CA,et al.Management of Helicobacter pylori infection-the Maastricht V/Flor-ence Consensus Report[J].Gut,2017,66(1):6-30． [4]Fallone CA,Chiba N,van Zanten SV,et al.The toronto consensus for the treatment of Helicobacter pylori infection in adults[J].Gastroenterology,2016,151(1):51-69. [5]刘文忠,谢勇,陆红,等.第五次全国幽门螺杆菌感染处理共识报告[J].胃肠病学,2017,22(6):346-360． [6]Smith SM,O’Morain C,McNamara D.Helicobacter pylori resistance to current therapies[J].Curr Opin Gastroenterol,2019,35(1):6-13． [7]Kuo YT,Liou JM,El-Omar EM,et al.Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region:a systematic revivew and meta-ananlysis[J].Lancet Gastroenterontl Hepatol,2017,2(10):707-715. [8]Sugimoto M,Sahara S,Ichikawa H,et al.Four-times-daily dosing of rabeprazole with sitafloxacin,high-dose amoxicillin,or both for metronidazole-resistant infection with Helicobacter pylori in Japan[J].Helicobacter,2017,22(1):e12319. [9]Hu Y,Zhu Y,Lu NH,et al.Novel and effective therapeutic regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance[J].Front Cell Infect Microbiol,2017(7):168. [10]Zullo A,Ridola L,Francesco VD,et al.High-dose esomeprazole and amoxicillin dual therapy for first-line Helicobacter pylori eradication:a proof of concept study[J].Annals of Gastroenterology,2015,28(4):448-451. [11]Yang JC,Lin CJ,Wang HL,et al.High-dose Dual Therapy Is Superior to Standard First-line or Rescue Therapy for Helicobacter pylori Infection[J].Journal of the American Gastroenterological Association,2015,13(5):895-905. [12]任玲,陆红,李海燕,等.以高剂量和普通剂量雷贝拉唑为基础的改良二联疗法根除幽门螺杆菌疗效初探[J].中华消化内镜杂志,2018(1):60-62． [13]Sapmaz F,Kalkan IH,Atasoy P,et al.A non-inferiority study:modified dual therapy consisting higer doses of rabeprazole is as successful as standard quadruple therapy in eradication of Helicobacter pylori[J].Am J Therapeut,2017,24(4):e393-e398. [14]Xue Y,Jin-Xia W,Sheng-Xi H,et al.High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment:A Systematic Review and Meta-Analysis[J].Medicine,2019(98):1-7. [15]Wongun K,Yunjeong L,Chiyeon L,et al.High Dose Ilaprazole/Amoxicillin as First-Line Regimen for Helicobacter pylori Infection in Korea[J].Gastroenterology Research and Practice,2016(2016):1-7. [16]Park HY,Kang EJ,Kim DG,et al．High and frequent dose of dexlansoprazole and amoxicillin dual therapy for Helicobacter pylori infections:A single arm prospective study[J].Korean J Gastroenterol,2017,70(4):176-180. [17]Gao CP,Zhou Z,Wang JZ,et al.Efficacy and safety of high-dose dual therapy for Helicobacter pylori rescue therapy: A systematic review and meta-analysis[J].J Dig Dis,2016,17(12):811-819． [18]Cui Y,Zhou K,Strugatsky D,et al.pH-dependent gating mechanism of the Helicobacter pylori urea channel revealed by cryo-EM[J].Science Advances,2019,5(3):eaav8423. [19]Juvale K,Purushothaman G,Singh V,et al.Identification of selective inhibitors of Helicobacter pylori IMPDH as a targeted therapy for the infection[J].Scientific Reports,2019,9(1):190. [20]Zhi X,Liu Y,Lin L,et al.Oral pH sensitive GNSab nanoprobes for targeted therapy of Helicobacter pylori without disturbance gut microbiome[J].Nanomedicine,2019(20):102019. [21]Zeng M,Mao XH,Li JX,et alEfficacy,safety,and immunogenicity of an oral recombinant Helicobacter pylori vaccine in children in China:a randomised，double-blind，placebo-conmtrolled，phase 3 trial[J].Lancet,2015,386(10002):1457-1464. [22]Huang Y,Hang X,Jiang X,et al.In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori[J].Antimicrob Agents Chemother,2019,63(6):e00004-e000019.

相似文献/References:

[1]郭绍敏.克拉霉素四联方案对一线方案根除失败的幽门螺杆菌的再根除效果评估[J].医学信息,2018,31(02):121.[doi:10.3969/j.issn.1006-1959.2018.02.044]
　GUO Shao-min.Evaluation of the Re-eradication Effect of Clarithromycin Quadruple Regimen on Helicobacter Pylori Eradication Failure in the First Line Scheme[J].Medical Information,2018,31(15):121.[doi:10.3969/j.issn.1006-1959.2018.02.044]
[2]罗宜辉,刘代华.益生菌联合四联方案根除幽门螺杆菌的临床研究[J].医学信息,2018,31(11):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
　LUO Yi-hui,LIU Dai-hua.Clinical Study on the Eradication of Helicobacter Pylori by Probiotics Combined with Quadruple Regimen[J].Medical Information,2018,31(15):25.[doi:10.3969/j.issn.1006-1959.2018.11.008]
[3]马艳会,寇 毅.幽门螺杆菌感染与结直肠腺瘤临床特征的相关性研究[J].医学信息,2022,35(16):102.[doi:10.3969/j.issn.1006-1959.2022.16.024]
　MA Yan-hui,KOU Yi.Correlation Between Helicobacter Pylori Infection and Clinical Features of Colorectal Adenoma[J].Medical Information,2022,35(15):102.[doi:10.3969/j.issn.1006-1959.2022.16.024]
[4]华启洋,吴同利,刘永艳,等.幽门螺杆菌在胃食管反流病发病中的作用[J].医学信息,2019,32(20):103.[doi:10.3969/j.issn.1006-1959.2019.20.029]
　HUA Qi-yang,WU Tong-li,LIU Yong-yan,et al.The Role of Helicobacter Pylori in the Pathogenesis of Gastroesophageal Reflux Disease[J].Medical Information,2019,32(15):103.[doi:10.3969/j.issn.1006-1959.2019.20.029]
[5]陶源,徐俊林,张艳,等.上消化道黏膜病变病理诊断结果分析[J].医学信息,2020,33(02):125.[doi:10.3969/j.issn.1006-1959.2020.02.036]
　TAO Yuan,XU Jun-lin,ZHANG Yan,et al.Analysis of Pathological Diagnosis for Upper Gastrointestinal Mucosal Lesions[J].Medical Information,2020,33(15):125.[doi:10.3969/j.issn.1006-1959.2020.02.036]
[6]周 政.胃息肉与幽门螺杆菌感染的关系[J].医学信息,2021,34(21):91.[doi:10.3969/j.issn.1006-1959.2021.21.023]
　ZHOU Zheng.Relationship Between Gastric Polyps and Helicobacter Pylori Infection[J].Medical Information,2021,34(15):91.[doi:10.3969/j.issn.1006-1959.2021.21.023]
[7]黄 飞.不同用药方案治疗幽门螺杆菌感染胃溃疡的效果比较[J].医学信息,2020,33(16):156.[doi:10.3969/j.issn.1006-1959.2020.16.050]
　HUANG Fei.Comparison of the Effects of Different Medication Regimens in the Treatment of Gastric Ulcer Infected by Helicobacter Pylori[J].Medical Information,2020,33(15):156.[doi:10.3969/j.issn.1006-1959.2020.16.050]
[8]王蓓蓓,白 梅.黄芪建中汤加减联合四联疗法对Hp阳性胃溃疡患者Hp清除率及复发率的影响[J].医学信息,2022,35(20):145.[doi:10.3969/j.issn.1006-1959.2022.20.040]
　WANG Bei-bei,BAI Mei.Effect of Huangqi Jianzhong Decoction Combined with Quadruple Therapy on Hp Clearance Rate and Recurrence Rate in Patients with Hp Positive Gastric Ulcer[J].Medical Information,2022,35(15):145.[doi:10.3969/j.issn.1006-1959.2022.20.040]
[9]张 静,张鸿博.中医药治疗幽门螺杆菌相关性胃溃疡研究[J].医学信息,2022,35(20):173.[doi:10.3969/j.issn.1006-1959.2022.20.048]
　ZHANG Jing,ZHANG Hong-bo.Study on Traditional Chinese Medicine Treatment of Helicobacter Pylori Associated Gastric Ulcer[J].Medical Information,2022,35(15):173.[doi:10.3969/j.issn.1006-1959.2022.20.048]
[10]张运林.铝碳酸镁片联合雷贝拉唑Hp感染合并活动性消化性溃疡的安全性[J].医学信息,2020,33(24):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]
　ZHANG Yun-lin.The Safety of Hydrotalcite Tablets Combined with Rabeprazole Hp Infection with Active Peptic Ulcer[J].Medical Information,2020,33(15):125.[doi:10.3969/j.issn.1006-1959.2020.24.035]

更新日期/Last Update: 1900-01-01